Revolutionizing Refinement of Cannabis & High Value Crops

SEPTEMBER 2023
Disclaimer

This documentation is a presentation (the “Presentation”) of general background information about CryoMass Technologies Inc. (“CryoMass” or “the Company”). It is information in a summary form and does not purport to be complete. It is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. These should be considered, with or without professional advice, when deciding if an investment is appropriate. This Presentation does not constitute or form part of any offer for sale or solicitation of any offer to buy or subscribe for securities nor shall it or any part of it form the basis of or be relied upon in connection with, or act as any inducement to enter into, any contract or commitment whatsoever. Recipients of this Presentation who are considering acquiring securities of CryoMass are referred to the entire body of publicly disclosed information regarding CryoMass. The information contained in this Presentation is derived solely from management of CryoMass and otherwise publicly available information concerning CryoMass and does not purport to be all-inclusive or form part of any offer for sale or solicitation of any offer to buy or subscribe for securities nor shall it or any part of it form the basis of or be relied upon in connection with, or act as any inducement to enter into, any contract or commitment whatsoever. The information has not been independently verified and is subject to material updating, revision and further amendment, and is qualified entirely by reference to CryoMass’ publicly disclosed information. No representation or warranty, express or implied, is made or given by or on behalf of CryoMass or any of its affiliates, directors, officers or employees as to the accuracy, completeness or fairness of the information or opinions contained in this Presentation and, if given and/or made, such information or representations must not be relied upon as having been so authorized. The information and opinions contained in this Presentation are provided as at the date of this Presentation. The contents of this Presentation are not to be construed as legal, financial or tax advice. Each prospective investor should contact its, her or its own legal adviser, independent financial adviser or tax adviser for legal, financial or tax advice.

Certain information set forth in this Presentation contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, any investment solicited; (iii) the expected development of the Company’s business, projects, and agreements; (iv) execution of the Company’s vision and growth strategy, including with respect to future contractual activity and global growth; (v) sources and availability of third-party financing for the Company’s projects; (vi) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; (vii) renewal of the Company’s material agreements; (viii) future liquidity, working capital, and capital requirements; and (ix) financial results, future financial position, expected growth of cash flows, business strategy, budgets, projected costs, projected capital expenditures, taxes, plans, objectives, potential synergies, industry trends and growth opportunities. Often but not always, forward-looking information can be identified by the use of words such as “anticipate”, “believe”, “expect”, “project”, “estimate”, “likely”, “intend”, “should”, “could”, “may”, “target”, “plan” and other similar expressions or variations (including negative variations) of such words and phrases. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance, achievements and financial results of CryoMass in future periods to differ materially from any projections of future performance, achievements or financial results expressed or implied by such forward-looking statements. These risks, uncertainties and other factors include, but are not limited to, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in Canada generally, income tax and regulatory matters; the ability of CryoMass to implement its business strategies; competition; crop failure; currency and interest rate fluctuations; and the other risks. The foregoing factors are not exhaustive and are not intended to be exhaustive. Although CryoMass has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended.

Although forward-looking statements contained in this Presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements contained herein are made as of the date hereof by the Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned to place undue reliance on forward-looking statements. All forward-looking statements is expressly qualified in its entirety by this cautionary statement. Forward-looking statements and agreements; (i) formation contained herein concerning management’s general expectations concerning the cannabis industry are based on estimates prepared by management using data from publicly available industry sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which management believes to be reasonable. However, this data is inherently imprecise, although generally indicative of relative market positions, market shares and performance characteristics. While management is not aware of any misstatements regarding any industry data presented herein, industry data is subject to change based on various factors. This Presentation may not be reproduced, further distributed or published in whole or in part by any other person. Neither this Presentation nor any copy of it may be taken or transmitted into or distributed in any other jurisdiction which prohibits the same except in compliance with applicable laws. Any failure to comply with this restriction may constitute a violation of applicable securities laws. Recipients are required to inform themselves of, and comply with, all such restrictions or prohibitions and CryoMass does not accept liability to any person in relation thereto.
CryoMass Technologies Inc. develops and licenses cutting-edge equipment and processes to refine harvested cannabis, hemp, and other premium crops. The company’s patented technology harnesses liquid nitrogen to reduce biomass and then efficiently isolate, collect and preserve delicate resin glands (trichomes) containing prized compounds like cannabinoids and terpenes.
Maximizing Returns for Cultivators and Processors of Premium Botanicals

- Building on this technology, CryoMass has engineered its premier Trichome Separation unit (CryoSift Separator™), optimized via patented cryogenic processes to rapidly capture intact, high-value cannabis and hemp trichomes (CryoSift™).

- Much like sugar and flour refinements, the resulting CryoSift™ concentrate is a superior product compared to unprocessed biomass.

- For cultivators, reducing biomass into CryoSift™ slashes volume up to 80%, dramatically lowering storage, handling, and transportation costs. Properly stored, CryoSift™ prevents potency and terpene degradation, preserving value.

- For processors, the minimized input volume also enables considerable cost savings and logistics advantages. Extracting from CryoSift™ using solvents and manufacturing solventless products unlocks industrial scale yields unattainable otherwise.

- CryoMass anticipates its efficiencies will catalyze industry-wide shifts in cannabis and hemp post-harvest methods. Additionally, the technology shows promise for diverse trichome-rich plants.
Hemp & Marijuana Are The Same Plant: Cannabis sativa

All forms of cannabis, including marijuana and hemp, belong to a single species - cannabis sativa.

HEMP

A term often used in policy to describe any cannabis variety with less than 0.3% THC.

Traditionally bred for CBD, fiber and seed

MARIJUANA

A vernacular term typically used to describe cannabis with higher levels of THC (over 10%).

Traditionally bred for cannabinoids – most notably THC
1. FLOWER
Often called buds, cannabis flowers vary in appearance depending on their sex and genetic traits. The colours range widely with the most common being green, orange, red and purple. The female flower, having the highest concentration of trichomes, is the part of the plant that is consumed to experience the effects attributed to cannabis.

2. TRICHOMES
Cannabis trichomes contain, in varying quantities, several cannabinoid compounds, predominantly tetrahydrocannabinol (THC) and cannabidiol (CBD). Trichomes appear as tiny crystals all over the plant. They are bigger and denser on the flowers than on the leaves.

3. LEAF
The symbol of the cannabis and something of an icon, the leaf is easily recognizable by its fan shape, pronounced venation and serrated leaflets. Leaf colour can range from pale green to dark olive green.

TERPENES
Different strains of cannabis have different sets of terpenes, which are comparable to essential oils. It is mainly the terpenes that give cannabis plants their particular aromas and flavours.
Importance Of Trichomes

Glandular trichomes are small resin glands found mostly on the surface of female flowers. These chemical factories produce hundreds of compounds including cannabinoids and terpenes. Cannabinoids, including THC and CBD, are responsible for the medicinal and sometimes psychoactive effects of cannabis.

Terpenes (and terpenoids) are largely responsible for the characteristic smell of cannabis as well as contributing to the medicinal effects. Cannabinoids and terpenes are found almost exclusively within the glandular trichomes and nowhere else on the plant. Not only are these compounds very sensitive to environmental factors such as oxygen, heat and light, the trichomes housing these compounds are very delicate and will readily fracture or detach when subjected to physical agitation.

WHY TRICHOMES?
Traditional Harvesting & Processing Methods Incur Enormous Loss Of Trichomes

Conventional processing methods haven’t changed much since the 1960s, when the industry operated illegally out of someone’s backyard. The methods waste a third or more of the plant’s most desired elements – the trichomes.

The trouble starts with the fragility of trichomes. They break off easily and are lost forever in the same way a Christmas tree loses its needles when handled and then are gone forever. With conventional handling and drying, every step shakes off more of them. All in all, roughly one-third of the trichomes are lost.

When the plant is handled and trucked to a drying facility, the loss of trichomes accelerates. Then – midway through drying – the flower becomes extremely brittle and trichome loss becomes exponential, like the needles of a Christmas tree being forced through the front door at the end of the holiday season.

By that point, the plant still needs to be handled and transported to the extraction facility. The biggest challenge in any plant processing is to capture all the valuable elements that are wrapped up inside the plant at the moment of harvest.

There really was no way to accomplish this...until now.
What Have Trichomes Been Traditionally Used For?

Hashish, also known as hash, is a cannabis concentrate product composed of compressed or purified preparations of stalked resin glands, called trichomes.

Hash has a long history of usage in countries such as Morocco, Afghanistan, India, Iran, Israel, and Lebanon. The sticky resins glands of the fresh flowering female cannabis plant are collected. Traditionally this was, and still is, done in remote locations by pressing or rubbing the flowering plant between two hands and then forming the sticky resins into a small ball of hashish called charas. This method produces the highest amount of cannabinoids (THC content up to 60%) without chemical solvents or distillation.

Mechanical separation methods use physical action to remove the trichomes from the dried plant material, such as sieving through a screen by hand or in motorized tumblers. This technique is known as "drysifting". The resulting powder, referred to as "kief" or "drysift", is compressed with the aid of heat into blocks of hashish.

Ice-water separation is another mechanical method of isolating trichomes.
How Were Trichomes Collected Before CryoMass?

Traditional trichome separation methods are rudimentary at best.

The cannabis flower is typically placed in a mesh bag, soaked in ice water and then agitated to separate the trichomes.

The careful agitation is done by machine or by hand, using paddles. Trichomes may break away from supporting flower and leaves when plant material becomes brittle at low temperatures. After plant material has been agitated in an icy slush, separated trichomes are often dense enough to sink to the bottom of the ice-water mixture following agitation, while lighter pieces of leaves, stems and other plant particles tend to float. The water is then left to settle and the trichomes at bottom of the tank are isolated using filtration bags with various-sized screens.
Current Industry Challenges

- Harvesting, drying and freezing biomass is labor intensive and costly.
- Biomass handling causes significant trichome loss (30%+).
- Biomass high storage and transport costs due to large volumes and space needs.
- Biomass degradation occurs during storage and handling resulting from exposure to oxygen, moisture, light or heat
- Extraction from full biomass is a lengthy and expensive process.

CryoMass delivers a state-of-the-art technology solution that addresses all these challenges to increase profitability for our customers.
Delivering High-Value Process Improvements to Biomass Operators

MOBILE OR FIXED UNITS
Our system can be operated at the cultivation site or be permanently installed in a processing facility.

SCALABLE INDUSTRIAL CAPACITY
Process up to 700 lbs/317,500 grams of fresh biomass per hour per system.

ELIMINATE DRYING
Process fresh whole plants straight from the field and reduce days of work & trichome loss.

GREEN PROCESS
Minimal energy usage and no organic solvents. Minimal ecological footprint.

HIGHER OUTPUT
Increase cannabinoid and terpene concentration up to 10x.

BIOMASS VERSATILITY
Process wet or dry, fresh frozen, whole plant, cured flower, trim and everything in between.

REDUCED VOLUME
Reduce volume of product up to 80% relative to starting material, making storage and transportation less burdensome.

SEPARATION EFFICIENCY
The process efficiently recovers up to 97% of available trichomes from biomass.
CryoMass vs. Traditional Trichome Separation Systems

When comparing the results of the patented CryoMass system to traditional ice water trichome separation systems, there is no comparison.

Based on the processing of 25,000 lbs of biomass, here is a comparison of our trichome separation system versus nine leading traditional systems that do not and cannot utilize our patented cryogenic, solventless separation process. They use ice water instead.

It is important to note that one of the key reasons the CryoMass system is so much more efficient from a process and cost-saving perspective is that it is, to the best of our knowledge, the only continuous-feed separation system while all others are batch-feed systems.

Although the Company's initial focus is on the cannabis and hemp sector, there is tremendous potential to generate important revenue streams from processing other high-value, trichome-rich plants where similar cost savings and end-product improvements can be realized.

* Traditional systems data was gathered from company websites and from conversations with company representatives. This is an average of the 9 leading traditional systems.
We Call The Result Of Our Cryogenic Trichome Separation - CryoSift™

CRYOSIFT™ IS TRICHOMES IN THEIR PUREST FORM

- CryoSift™ can be used for making THC and CBD products for medicinal, wellness and recreational purposes. It can also be used for making CBD products for animals.

- The quality of CryoSift™ is superior to sift obtained with traditional dry and water-based trichome separation methods. Cryogenic separation results in increased cannabinoid yields, higher terpene count for a greater retention of the most desirable compounds.

- Though CryoSift™ can be consumed as is, it is the ideal input for manufacturing superior premium concentrates at scale, without the use of solvents (solventless).

- CryoSift™ can also be used as a high-quality feedstock for traditional solvent-based extraction methods (such ethanol, CO2 or hydrocarbon) to create extracts with different flavor, color and aroma profiles like live resin concentrates.
Attractive Opportunities in Botanical Extracts Markets

Cannabis and Hemp - Our First Major Markets

Global Botanical Extracts - The Future

* Management estimates based on data compiled from a variety of sources, including, but not limited to: industry research reports, publicly-traded company filings, industry trade associations, trade publications and market research databases. Additional data regarding data sources available upon request.
Building A Sustainable Competitive Advantage

Strong IP portfolio

- US Patent:
  - System and method for cryogenic separation of plant material
  - Patent #: 10,864,525
  - 2038-04-21: Expiration

- Patents also granted in Canada (# 3,064,896) and China.
- Patents pending in 5 other countries.
- Trademarks: CryoMass®, CryoSift™ and CryoSift Separator™

- Experienced in-house team of industry-leading experts.
- Established industry relationships.
- Extensive R&D and long learning curve.
- Significant capital investment to develop the technology and supporting processes.
- First mover advantage.
Strategic Partners and Customers

- Strategic Operational Partners are established, licensed biomass processors.
- Customers are existing, established cultivators and processors of biomass.

June 14th 2023, CryoMass first showcasing event for cultivators and processors from California and other states.
Recurring Revenue Model

- CryoMass licenses its patented technology by renting CryoSift Separators™ to partners who provide biomass refinement services to cultivators and processors of premium crops.

- Our licensing model generates recurring revenue by charging partners a percentage of the revenue they generate by converting biomass into CryoSift™, which is further refined into products.

Licensing model economics summary:

1. Upfront equipment licensing fee.
2. Recurring royalty as percentage of toll processing revenues and CryoSift™ derived product revenues.
Example of Recurring Royalties per Unit

<table>
<thead>
<tr>
<th>Year</th>
<th>2024</th>
<th>2025</th>
<th>2026</th>
<th>2027</th>
<th>2028</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pounds of biomass per hour processed by the CryoSift Separator™</td>
<td>500</td>
<td>500</td>
<td>500</td>
<td>500</td>
<td>500</td>
</tr>
<tr>
<td>Hours of operation per day</td>
<td>5</td>
<td>6</td>
<td>8</td>
<td>10</td>
<td>12</td>
</tr>
<tr>
<td>Days of operation per week</td>
<td>4</td>
<td>4</td>
<td>5</td>
<td>5</td>
<td>6</td>
</tr>
<tr>
<td>Week of operation per year</td>
<td>48</td>
<td>48</td>
<td>48</td>
<td>48</td>
<td>48</td>
</tr>
<tr>
<td>Royalty per pound paid to CryoMass</td>
<td>$4.00</td>
<td>$4.00</td>
<td>$4.00</td>
<td>$4.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Annual royalty paid to CryoMass by the licensee per unit</td>
<td>$1,920,000</td>
<td>$2,304,000</td>
<td>$3,840,000</td>
<td>$4,800,000</td>
<td>$6,912,000</td>
</tr>
</tbody>
</table>

CryoSift Separator™ Unit Deployment Targets

<table>
<thead>
<tr>
<th>Year</th>
<th>2024</th>
<th>2025</th>
<th>2026</th>
<th>2027</th>
<th>2028</th>
</tr>
</thead>
<tbody>
<tr>
<td>CryoSift Separators™ deployed during the year</td>
<td>6</td>
<td>8</td>
<td>10</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>Total CryoSift Separators™ deployed at year end *</td>
<td>8</td>
<td>16</td>
<td>26</td>
<td>38</td>
<td>50</td>
</tr>
</tbody>
</table>

* 2024 Includes 2 CryoSift Separators™ deployed by the end of 2023

Disclaimer: ** The theoretical recurring royalties above are based on management conservative estimates and assumptions of future performance and operations under a per-pound fee model that includes a fee of $8.00 USD per pound charged by the licensee to its customers of which CryoMass is getting 50%. Each licensing contract will be negotiated on a case-by-case basis. Market dynamics can vary greatly due to a multitude of factors and therefore, the actual results, performance or achievements of the Company can be materially different from any future results, performance or achievements expressed or implied by the assumptions above.
CryoSift Separators™
Cannabis & Hemp Markets

- **Leads:** 200+ inquiries received from 10+ countries and 20+ US States.
- **Prospects:** 70+ conversations.
- **Opportunities:** 25+ active conversations.
- **Targets:** 2 short term deployments.
- **Operational:** 1 CryoSift Separator™ in California, USA.
Global cannabis product sales are projected to reach US$61 billion by 2026 (1)

Initial Market Focus
Is North America

CALIFORNIA
1st CryoSift Separator™ at operating partner facility can cover 60% of California cultivation licenses.

Legal Cannabis product sales in California totalled US$431.3 million in June 2022.
Suggesting an annual run-rate of US$5.175 billion (6)

CANADA CANNABIS
Product sales of US$4 billion in 2021 projected to be US$7.6 billion in 2026 (2)
2,196 acres of licensed cultivation in 2021 (3)

CANADA HEMP
1,269 industrial hemp licenses in 2020 with 54,963 acres of cultivation (5)

USA CANNABIS
Product sales projected to grow from US$18.5 billion in 2022 to US$58.8 billion in 2026 (2)

USA HEMP
In 2021, 30,000 acres of hemp were harvested for a total of ~30 million pounds of biomass (4)

Christian Noël
CEO
Seasoned wealth advisor, investor and cannabis industry expert leveraging over 20 years of capital markets expertise to drive growth opportunities.

Blair Mullin
CFO
Decades of CFO leadership spanning high-growth startups to public companies across technology, manufacturing, and emerging industries.

Patricia Kovacevic
General Counsel & Head of External Affairs
Accomplished legal expert and strategist with decades of experience navigating complex regulations for global corporations across multiple industries.

Aaron Godin
Director of Applied Science
A Master agrologist with a passion for everything driven by science and data.

Mike Stringile
Director of Int’l Sales
Extraction technology expert leveraging 7+ years of oil, gas and cannabis industry experience to drive innovative solutions and sales growth.

Steve Cimini
Director of US Sales
Cannabis industry pioneer and sales leader instrumental in developing revolutionary extraction technologies and achieving tremendous market growth.

Patricia Kovacevic
General Counsel & Head of External Affairs

Steve Cimini
Director of US Sales

Christian Noël
CEO
Seasoned wealth advisor, investor and cannabis industry expert leveraging over 20 years of capital markets expertise to drive growth opportunities.

Blair Mullin
CFO
Decades of CFO leadership spanning high-growth startups to public companies across technology, manufacturing, and emerging industries.

Patricia Kovacevic
General Counsel & Head of External Affairs
Accomplished legal expert and strategist with decades of experience navigating complex regulations for global corporations across multiple industries.

Aaron Godin
Director of Applied Science
A Master agrologist with a passion for everything driven by science and data.

Mike Stringile
Director of Int’l Sales
Extraction technology expert leveraging 7+ years of oil, gas and cannabis industry experience to drive innovative solutions and sales growth.

Steve Cimini
Director of US Sales
Cannabis industry pioneer and sales leader instrumental in developing revolutionary extraction technologies and achieving tremendous market growth.

Matt Armstrong
Sr. Director of Innovation
Decorated Marine veteran and technical visionary leading cutting-edge cryogenic innovation in agricultural extraction technology.

Priyesh Sharma
Sr. Director of Engineering and R&D
Engineering leader with 20+ years’ experience driving innovation from concept to commercialization across agriculture, energy, aerospace, and other industries.
Board Of Directors

Dr. Delon Human
Chairman of the Board
Accomplished physician, author and global health strategist advising international organizations, governments and corporations on healthcare access, harm reduction, and product transformation.

Mario Gobbo
Director
Seasoned investment banker and biotech advisor with 35+ years spanning healthcare, life sciences, and energy sectors across emerging and developed markets.

Mark Radke
Director
Preeminent securities lawyer and former SEC Chief of Staff advising financial services institutions on regulatory compliance, governance, and strategic initiatives.

Simon Langelier
Director
Global tobacco executive with 30+ years of leadership spanning new product innovation, international markets, and strategic board governance.
<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Where it Began</td>
<td>August 2015</td>
<td>The concept of using cryogenic fluid to separate trichomes &amp; produce extracts without solvents was born in California.</td>
</tr>
<tr>
<td>Early R&amp;D</td>
<td>March 2016</td>
<td>First separation of trichomes from biomass using cryogenic fluid was performed in Long Beach, California.</td>
</tr>
<tr>
<td>Establishing Patents</td>
<td>June 2016</td>
<td>Matt Armstrong began writing the cryogenic separation patent with the intent to keep it as broad as possible.</td>
</tr>
<tr>
<td>Patent Applications</td>
<td>May 2017</td>
<td>Official patent applications with the US patent office (USPTO), European patent office (EPO) &amp; many other countries.</td>
</tr>
<tr>
<td>Testing 1st Prototype</td>
<td>June 2020</td>
<td>Began assembling and testing of 1st generation CryoCann prototype.</td>
</tr>
<tr>
<td>US Patent Granted</td>
<td>December 2020</td>
<td>Approval &amp; grant date of initial patent (valid until 2038) by The United States Patent and Trademark Office (USPTO).</td>
</tr>
<tr>
<td>Dev 2nd Prototype</td>
<td>April 2021</td>
<td>Began 2nd generation CryoCann system design with California based manufacturer.</td>
</tr>
<tr>
<td>CryoCann Acquired</td>
<td>June 2021</td>
<td>CryoCann USA assets are acquired by CryoMass Technologies Inc.</td>
</tr>
<tr>
<td>Further Testing</td>
<td>December 2021</td>
<td>Began testing of individual components of the 2nd generation prototype.</td>
</tr>
<tr>
<td>CAN Patent Granted</td>
<td>April 2022</td>
<td>CryoMass receives Canadian patent (valid until 2039) and begins real-time trials of a full-scale, user-ready model of its patented cryogenic trichome separation unit.</td>
</tr>
<tr>
<td>First Unit Dispatched</td>
<td>December 2022</td>
<td>Delivery of our CryoSift Separator™ Beta Unit at operating partner facility in California.</td>
</tr>
<tr>
<td>First Multi-State License Agreement</td>
<td>January 2023</td>
<td>CryoMass signed its first Multi-State License Agreement for CryoSift Separators™.</td>
</tr>
<tr>
<td>California License Agreement</td>
<td>August 2023</td>
<td>CryoMass Partners with California Manufacturer to Revolutionize Cannabinoid Production.</td>
</tr>
<tr>
<td>CAN Patent Granted</td>
<td>April 2022</td>
<td>CryoMass receives Canadian patent (valid until 2039) and begins real-time trials of a full-scale, user-ready model of its patented cryogenic trichome separation unit.</td>
</tr>
</tbody>
</table>
A Game-Changing Opportunity

MARKET
Large & rapidly growing market opportunity for premium botanical extracts of $25B today to more than $95B in 2030.

TECHNOLOGY
Superior patented technology for premium botanical refinement delivers efficient, high value solution to customers.

ECONOMICS
Attractive, high margin recurring revenue model.

IP
Solid IP portfolio - patented core technology.

UNPARALLELED
Limited competition from inferior refinement methodologies.

TEAM
Experienced senior management and Board with deep industry expertise and network.
To Learn More

The common stock of CryoMass Technologies Inc. trades on the OTCQB market under the symbol **CRYM**.

For further information, please contact us using a method below:

investors@cryomass.com  +1 (833) 256-2382  or  +1 (303) 222-8092

**WE WELCOME YOUR INQUIRIES**

WWW.CRYOMASS.COM